Precision Cancer Imaging Global Market Report 2026

Precision cancer imaging refers to an advanced medical imaging approach that utilizes highly accurate and targeted imaging techniques to detect, characterize, and monitor cancer at an early stage. It integrates modalities such as molecular imaging, functional imaging, and high-resolution anatomical imaging to improve diagnostic accuracy and support personalized cancer treatment planning.

The primary components of precision cancer imaging include hardware, software, and services. Hardware refers to advanced imaging equipment and systems utilized to capture high-resolution anatomical and functional images for accurate cancer detection and treatment planning. The types of cancer include breast cancer, lung cancer, prostate cancer, colorectal cancer, and other cancer types and the imaging modalities include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), single photon emission computed tomography (SPECT), and other modalities. They find application in cardiovascular, neurology, gastroenterology, infectious diseases, oncology, and other applications, serving end users including hospitals and clinics, diagnostic imaging centers, ambulatory surgical centers, and other end-users.

Tariffs are influencing the precision cancer imaging market by raising the cost of imported imaging equipment, semiconductor components, contrast agents, and advanced diagnostic software required for precision oncology diagnostics. This is slowing the procurement and deployment of MRI, CT, PET, and SPECT imaging systems, particularly in regions dependent on imported medical technologies such as Asia-Pacific and Latin America. Hardware-intensive segments such as imaging systems, detection devices, and radiation equipment are most affected due to global supply chain dependencies. However, tariffs are also encouraging local manufacturing, regional supplier diversification, and increased investment in domestic medical imaging technology ecosystems, creating long-term resilience in the market.

The precision cancer imaging market research report is one of a series of new reports from The Business Research Company that provides precision cancer imaging market statistics, including precision cancer imaging industry global market size, regional shares, competitors with a precision cancer imaging market share, detailed precision cancer imaging market segments, market trends and opportunities, and any further data you may need to thrive in the precision cancer imaging industry. This precision cancer imaging market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The precision cancer imaging market size has grown rapidly in recent years. It will grow from $17.39 billion in 2025 to $19.58 billion in 2026 at a compound annual growth rate (CAGR) of 12.6%. The growth in the historic period can be attributed to rising prevalence of cancer cases, advancements in molecular imaging technologies, increasing adoption of PET and MRI systems, expansion of hospital diagnostic infrastructure, growth in government cancer screening initiatives.

The precision cancer imaging market size is expected to see rapid growth in the next few years. It will grow to $31.71 billion by 2030 at a compound annual growth rate (CAGR) of 12.8%. The growth in the forecast period can be attributed to increasing demand for personalized oncology treatments, expansion of AI-driven imaging analytics, growing investments in precision medicine research, rising adoption of cloud-based imaging platforms, increasing development of non-invasive diagnostic solutions. Major trends in the forecast period include precision oncology imaging adoption, hybrid imaging system integration, multi-modal diagnostic workflows, radiomics-based tumor characterization, early-stage cancer detection advancements.

The rising prevalence of cancer cases is expected to propel the growth of the precision cancer imaging market going forward. The rising prevalence of cancer cases is primarily due to an aging population, as older individuals have a higher risk of developing cancer because of the accumulation of genetic mutations and longer exposure to risk factors over time. Precision cancer imaging supports cancer management by enabling earlier detection, more accurate tumor localization, and personalized treatment planning that improves therapeutic outcomes and reduces unnecessary interventions. For instance, in February 2024, according to the World Health Organization, over 35 million new cancer cases are predicted in 2050, a 77% increase from the estimated 20 million cases in 2022. Therefore, the rising prevalence of cancer cases is driving the growth of the precision cancer imaging market.

Leading companies operating in the precision cancer imaging market are concentrating on leveraging innovative technologies such as artificial intelligence-built imaging platforms to enhance diagnostic accuracy and streamline cancer treatment planning. Artificial intelligence-built imaging platforms are advanced CT and MR systems that utilize machine learning algorithms to improve image reconstruction, tumor detection, and anatomical visualization, helping clinicians achieve faster, more accurate diagnoses and more precise cancer treatment planning. For instance, in September 2025, Koninklijke Philips N. V. unveiled its latest CT and MR solutions at the American Society for Radiation Oncology (ASTRO) 2025 meeting, specifically designed to advance precision cancer care. These platforms feature ultra-fast AI-assisted reconstruction, helium-free MR systems for sustainable operation, extended field-of-view 4D imaging, and intuitive interfaces that streamline radiation therapy planning and improve patient comfort. By combining high image quality with efficient workflows, these innovations enable oncology teams to deliver personalized treatment with greater confidence and precision.

In January 2025, Telix Pharmaceuticals Limited acquired ImaginAb Inc. for an undisclosed amount. Through this acquisition, Telix Pharmaceuticals aims to strengthen its radiopharmaceutical and precision oncology pipeline by integrating next-generation biologics and antibody-based imaging technologies to enhance target identification, improve therapeutic development capabilities, and accelerate its expansion in precision cancer diagnostics and therapy. ImaginAb Inc. is a US-based biotechnology company specializing in precision cancer imaging, focusing on immuno-oncology imaging to provide actionable insights for patient selection and treatment progress.

Major companies operating in the precision cancer imaging market are Hitachi Medical Corporation, Thermo Fisher Scientific Inc., Siemens Healthineers AG, FUJIFILM Holdings Corporation, Koninklijke Philips N. V., GE HealthCare Technologies Inc., Shimadzu Corporation, Agilent Technologies Inc., Mindray Bio-Medical Electronics Co Ltd., Bruker Corporation, Canon Medical Systems Corporation, Shanghai United Imaging Healthcare Co Ltd., Agfa-Gevaert N. V., Hologic Inc., Carestream Health Inc., Perceptive Discovery, Esaote S. p. A., Alliance Medical Group, Quibim S. L., Mediso Ltd

North America was the largest region in the precision cancer imaging market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the precision cancer imaging market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the precision cancer imaging market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The precision cancer imaging market consists of revenues earned by entities by providing services such as tumor detection imaging services, cancer diagnosis and characterization services, image-guided biopsy support services, AI-based imaging analysis services, and treatment monitoring and response assessment services. The market value includes the value of related goods sold by the service provider or included within the service offering. The precision cancer imaging market also includes sales of positron emission tomography (PET) tracers, computed tomography (CT) contrast agents, magnetic resonance imaging (MRI) contrast agents, ingle photon emission computed tomography (SPECT) radiotracers, and hybrid imaging systems. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Precision Cancer Imaging Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses precision cancer imaging market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for precision cancer imaging ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The precision cancer imaging market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Component: Hardware; Software; Services
• 2) By Cancer Type: Breast Cancer; Lung Cancer; Prostate Cancer; Colorectal Cancer; Other Cancer Types
• 3) By Imaging Modality: Magnetic Resonance Imaging (MRI); Computed Tomography (CT); Positron Emission Tomography (PET); Single Photon Emission Computed Tomography (SPECT); Other Modalities
• 4) By Application: Cardiovascular; Neurology; Gastroenterology; Infectious Diseases; Oncology; Other Applications
• 5) By End-user: Hospitals And Clinics; Diagnostic Imaging Centers; Ambulatory Surgical Centers; Other End-users
• Subsegments:
• 1) By Hardware: Imaging Systems; Detection Devices; Radiation Equipment; Biopsy Guidance Systems; Monitoring Devices
• 2) By Software: Image Analysis Software; Visualization Software; Data Management Software; Diagnostic Software; Reporting Software
• 3) By Services: Imaging Services; Consulting Services; Maintenance Services; Training Services; Integration Services
• Companies Mentioned: Hitachi Medical Corporation; Thermo Fisher Scientific Inc.; Siemens Healthineers AG; FUJIFILM Holdings Corporation; Koninklijke Philips N.V.; GE HealthCare Technologies Inc.; Shimadzu Corporation; Agilent Technologies Inc.; Mindray Bio-Medical Electronics Co Ltd.; Bruker Corporation; Canon Medical Systems Corporation; Shanghai United Imaging Healthcare Co Ltd.; Agfa-Gevaert N.V.; Hologic Inc.; Carestream Health Inc.; Perceptive Discovery; Esaote S.p.A.; Alliance Medical Group; Quibim S.L.; Mediso Ltd
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.